WallStreetZenWallStreetZen

NASDAQ: LVTX
Lava Therapeutics Nv Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LVTX

Based on 2 analysts offering 12 month price targets for Lava Therapeutics Nv

Min Forecast
$1.24-23.69%
Avg Forecast
$1.37-15.69%
Max Forecast
$1.50-7.69%

Should I buy or sell LVTX stock?

Based on 2 analysts offering ratings for Lava Therapeutics Nv.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
2 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LVTX stock forecasts and price targets.

LVTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-05
lockedlocked$00.00+00.00%2025-08-05

1 of 1

Forecast return on equity

Is LVTX forecast to generate an efficient return?

Company
-28.94%
Industry
237.05%
Market
146.76%
LVTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LVTX forecast to generate an efficient return on assets?

Company
-9.53%
Industry
106.33%
LVTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LVTX earnings per share forecast

What is LVTX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.86
Avg 2 year Forecast
-$0.51
Avg 3 year Forecast
-$0.38

LVTX revenue forecast

What is LVTX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%
LVTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LVTX revenue growth forecast

How is LVTX forecast to perform vs Biotechnology companies and vs the US market?

Company
-100%
Industry
106.8%
Market
26.17%
LVTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LVTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LVTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LVTX$1.63$1.37-15.69%Hold
VERU$2.95$20.00+577.97%Buy
LTRN$4.01N/AN/A
PDSB$0.94$13.00+1,290.37%Buy
TVRD$4.65$55.50+1,093.55%Strong Buy
View Top Biotech Stocks

Lava Therapeutics Nv Stock Forecast FAQ

Is Lava Therapeutics Nv Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: LVTX) stock is to Hold LVTX stock.

Out of 2 analysts, 0 (0%) are recommending LVTX as a Strong Buy, 0 (0%) are recommending LVTX as a Buy, 2 (100%) are recommending LVTX as a Hold, 0 (0%) are recommending LVTX as a Sell, and 0 (0%) are recommending LVTX as a Strong Sell.

If you're new to stock investing, here's how to buy Lava Therapeutics Nv stock.

What is LVTX's earnings growth forecast for 2025-2027?

(NASDAQ: LVTX) Lava Therapeutics Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.92%.

Lava Therapeutics Nv's earnings in 2025 is -$33,004,651.On average, 4 Wall Street analysts forecast LVTX's earnings for 2025 to be -$22,538,377, with the lowest LVTX earnings forecast at -$21,654,519, and the highest LVTX earnings forecast at -$23,201,270. On average, 4 Wall Street analysts forecast LVTX's earnings for 2026 to be -$13,415,700, with the lowest LVTX earnings forecast at -$13,662,970, and the highest LVTX earnings forecast at -$12,981,663.

In 2027, LVTX is forecast to generate -$9,927,618 in earnings, with the lowest earnings forecast at -$12,374,011 and the highest earnings forecast at -$7,181,346.

What is LVTX's revenue growth forecast for 2025-2027?

(NASDAQ: LVTX) Lava Therapeutics Nv's forecast annual revenue growth rate of -100% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.17%.

Lava Therapeutics Nv's revenue in 2025 is $5,802,325.On average, 4 Wall Street analysts forecast LVTX's revenue for 2025 to be $0, with the lowest LVTX revenue forecast at $0, and the highest LVTX revenue forecast at $0. On average, 4 Wall Street analysts forecast LVTX's revenue for 2026 to be $0, with the lowest LVTX revenue forecast at $0, and the highest LVTX revenue forecast at $0.

In 2027, LVTX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is LVTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: LVTX) forecast ROA is -9.53%, which is lower than the forecast US Biotechnology industry average of 106.33%.

What is LVTX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year LVTX price target, the average LVTX price target is $1.37, with the highest LVTX stock price forecast at $1.50 and the lowest LVTX stock price forecast at $1.24.

On average, Wall Street analysts predict that Lava Therapeutics Nv's share price could fall to $1.37 by Aug 5, 2026. The average Lava Therapeutics Nv stock price prediction forecasts a potential downside of 15.69% from the current LVTX share price of $1.63.

What is LVTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: LVTX) Lava Therapeutics Nv's current Earnings Per Share (EPS) is -$1.23. On average, analysts forecast that LVTX's EPS will be -$0.86 for 2025, with the lowest EPS forecast at -$0.82, and the highest EPS forecast at -$0.88. On average, analysts forecast that LVTX's EPS will be -$0.51 for 2026, with the lowest EPS forecast at -$0.52, and the highest EPS forecast at -$0.49. In 2027, LVTX's EPS is forecast to hit -$0.38 (min: -$0.47, max: -$0.27).

What is LVTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: LVTX) forecast ROE is -28.94%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.